{"id":827203,"date":"2025-03-18T16:11:30","date_gmt":"2025-03-18T20:11:30","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/oncocyte-to-release-fourth-quarter-2024-results-on-march-24-2025\/"},"modified":"2025-03-18T16:11:30","modified_gmt":"2025-03-18T20:11:30","slug":"oncocyte-to-release-fourth-quarter-2024-results-on-march-24-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/oncocyte-to-release-fourth-quarter-2024-results-on-march-24-2025\/","title":{"rendered":"Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">IRVINE, Calif., March  18, 2025  (GLOBE NEWSWIRE) &#8212; Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that it will report fourth quarter 2024 financial results after the market closes on Monday, March 24, 2025. Oncocyte will host a live Zoom webinar to discuss the company&#8217;s financial results at 2:00 p.m. PT that same day.<\/p>\n<p align=\"left\">The live webinar to discuss financial results, followed by Q&amp;A, will be accessible via registration at the following link: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=CY6dSzKfhr-oBbjFHZaoBtas4VxSEk10jkQeT1ggaxNMKoAcbZ_1ehFCF7agS0eIIHS6FtbhJzWkgZ93-kcxakPWXlaAUt_zRIBbMptAEwXc6b-T0JdlfrLtiAFIfNs2_xxpN5xDyrIqfDA4aD8cjTCoR-SC1Bf2vlUtmTGWp4o=\" rel=\"nofollow\" target=\"_blank\">Oncocyte Q4 2024 Earnings Webinar<\/a>.<\/p>\n<p>An archived replay will be available after the call concludes on Oncocyte\u2019s investor relations website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ZgqEuwhp2cdAjGGBXPZx9w7XM_PaoTjpVVj5Wi01xphHpyCr6i1TO8aE_fmsAz2G-EF-TPgEPVtPUPkZgaZ7e3J7q2tRDXRPhR888sIDOtjiZY43DMpCuSn8z8aLsQCK\" rel=\"nofollow\" target=\"_blank\">https:\/\/investors.oncocyte.com<\/a>.<\/p>\n<p>\n        <strong>About Oncocyte<\/strong><br \/>\n        <br \/>Oncocyte is a leading diagnostics technology company. The company\u2019s tests are designed to help provide clarity and confidence to physicians and their patients. VitaGraft\u2122 is a clinical blood-based solid organ transplantation monitoring test. GraftAssure\u2122 is a research use only (RUO) blood-based solid organ transplantation monitoring test. DetermaIO\u2122 is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaCNI\u2122 is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. For more information about Oncocyte, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ZgqEuwhp2cdAjGGBXPZx9xcLERfpHb63a1RSvMOmtfub35yhPwiNwZCl-B1YVKdhKatTBUivC0kO_zirq509sAA8W39EWy8d22RTDAF8-lo=\" rel=\"nofollow\" target=\"_blank\">https:\/\/oncocyte.com\/<\/a>. For more information about our products, please visit the following web pages:<\/p>\n<p>\n        <strong>VitaGraft Kidney\u2122 &#8211; <\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ZgqEuwhp2cdAjGGBXPZx9xcLERfpHb63a1RSvMOmtfsTaLyFklrhZ-lVh-k39Fi1-fOHSVbsYjIeT0V0i2JhUOxtQrb9HkZfbPN8vott-uzY9WKWLZmHssGpGWsAcL7CHTEp-H3qvXY-M2-4BdX5Zg==\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <strong>https:\/\/oncocyte.com\/vitagraft-kidney\/<\/strong><br \/>\n        <\/a><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=YdeA4df2lMU4endULOvwdVBVr8_GyFA3A8ywdwXI9zmurg5a8DN1bnfcVRTvYthn1RS83tEbU19qwYN8YlPENfdOuuXo7ptw_NreiSLU_M8=\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <br \/>\n        <\/a><br \/>\n        <strong>VitaGraft Liver\u2122 &#8211; <\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ZgqEuwhp2cdAjGGBXPZx9xcLERfpHb63a1RSvMOmtftDgpYUmVhDosJa-7fJ-a53iaw5sIGeumThzw84O5cGQAM5j_95T51t4eajAOJhuZ8MyDzTaWIuBr0fFwzQZG50LJWyYU_R5GoXDwwlJBKfOw==\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <strong>https:\/\/oncocyte.com\/vitagraft-liver\/<\/strong><br \/>\n        <\/a><br \/>\n        <br \/>\n        <strong>GraftAssure\u2122 &#8211; <\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ZgqEuwhp2cdAjGGBXPZx9xcLERfpHb63a1RSvMOmtfs_Ythue8BGV6hxaqmhhHtnMr3WW_DyVdYt2CcspPI4upM9vYhPPAZH75SvtNE1f0CxBrDTrZFRQegHDNdv5hQT\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <strong>https:\/\/oncocyte.com\/graftassure\/<\/strong><br \/>\n        <\/a><br \/>\n        <br \/>\n        <strong>DetermaIO\u2122 &#8211; <\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ZgqEuwhp2cdAjGGBXPZx9xcLERfpHb63a1RSvMOmtfvkaShzYO8n242ADe1EN7o5BA8lbGK5f03aal0BBj1XEFIs4_uEKUVFUuaRdyyDlSkP3KIv-jSfEEg9ag8KIAMi\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <strong>https:\/\/oncocyte.com\/determa-io\/<\/strong><br \/>\n        <\/a><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=lZ-D2BEZUS_j-CMbXXsDjOQjsyWcvoNpBy377bu2KEDhBj0aA3DzBhIjk3XAh18M63aL4lvUdqHFKingOu2crA==\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <br \/>\n        <\/a><br \/>\n        <strong>DetermaCNI\u2122 &#8211; <\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ZgqEuwhp2cdAjGGBXPZx9xcLERfpHb63a1RSvMOmtfsBp9aI6NvCLUyBogXrxcsD-BCPmHiVDoX3laPJgff-_-aJWjHnlHoZ5WbhGIKSJGSHOYbC56OkMUldF9vPpQkp\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <strong>https:\/\/oncocyte.com\/determa-cni\/<\/strong><br \/>\n        <\/a>\n      <\/p>\n<p>\n        <strong>VitaGraft\u2122, GraftAssure\u2122, DetermaIO\u2122, and DetermaCNI\u2122 are trademarks of Oncocyte Corporation.<\/strong>\n      <\/p>\n<p>\n        <strong>CONTACT:<\/strong><br \/>\n        <br \/>Jeff Ramson<br \/>PCG Advisory<br \/>(646) 863-6893<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xKvODm-knvC7HUdkXJrTfZEZ5mCvGcPf0jpwBYW6jUVxj2SlCq_yoommqXyteXvq8En5Vrrf7rDUdkkEK5XUXncFjNBLtUO-V7lgwWf1iyI5S-3i6ncFkDzH7jG2KTAoasjDmrMChgz56bpzOHSeAkZlDEO02iibhGKnN8LVqGc-ZdxKiyvAupNfmL77umRs7qAGikO1oMmlqXMlJfj2cxH1VD4aunVzhFRrGc8oLozGfEO78zKLBWn17CE2uUXxG_LRnWucf_bfFJOt7oS4buur7Ud59VCAAoIYboGuFIoIur9DEd9YvKibBFMpIbKtf8S8xHn-I87djwEiyIZhBSWTJHYhIrREreQQfidl0IAxVd2yLnt-fTeTo_Sbumz7d_oarQkiE4J11tcC7G2i2xRIlda9V1KEV2Rq5E6b0QAPZlMsqBraaZwjDhHL1k_4Y12bjRyM8hHi_sl-s7bjmnpQDd6fVR7mDUnJxXokGu4Q-0z8LLJoFdRrDf85trk_\" rel=\"nofollow\" target=\"_blank\">jramson@pcgadvisory.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NjUwNyM2ODEyMTA1IzUwMDExOTgzOQ==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NzAyOWMxZmYtOWNhMi00MDdkLTllNmQtMGE2OWNiNjZmN2I0LTUwMDExOTgzOS0yMDI1LTAzLTE4LWVu\/tiny\/OncoCyte-Corporation.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>IRVINE, Calif., March 18, 2025 (GLOBE NEWSWIRE) &#8212; Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that it will report fourth quarter 2024 financial results after the market closes on Monday, March 24, 2025. Oncocyte will host a live Zoom webinar to discuss the company&#8217;s financial results at 2:00 p.m. PT that same day. The live webinar to discuss financial results, followed by Q&amp;A, will be accessible via registration at the following link: Oncocyte Q4 2024 Earnings Webinar. An archived replay will be available after the call concludes on Oncocyte\u2019s investor relations website at https:\/\/investors.oncocyte.com. About Oncocyte Oncocyte is a leading diagnostics technology company. The company\u2019s tests are designed to help provide clarity and confidence to physicians &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/oncocyte-to-release-fourth-quarter-2024-results-on-march-24-2025\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-827203","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/oncocyte-to-release-fourth-quarter-2024-results-on-march-24-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"IRVINE, Calif., March 18, 2025 (GLOBE NEWSWIRE) &#8212; Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that it will report fourth quarter 2024 financial results after the market closes on Monday, March 24, 2025. Oncocyte will host a live Zoom webinar to discuss the company&#8217;s financial results at 2:00 p.m. PT that same day. The live webinar to discuss financial results, followed by Q&amp;A, will be accessible via registration at the following link: Oncocyte Q4 2024 Earnings Webinar. An archived replay will be available after the call concludes on Oncocyte\u2019s investor relations website at https:\/\/investors.oncocyte.com. About Oncocyte Oncocyte is a leading diagnostics technology company. The company\u2019s tests are designed to help provide clarity and confidence to physicians &hellip; Continue reading &quot;Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/oncocyte-to-release-fourth-quarter-2024-results-on-march-24-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-18T20:11:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NjUwNyM2ODEyMTA1IzUwMDExOTgzOQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncocyte-to-release-fourth-quarter-2024-results-on-march-24-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncocyte-to-release-fourth-quarter-2024-results-on-march-24-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025\",\"datePublished\":\"2025-03-18T20:11:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncocyte-to-release-fourth-quarter-2024-results-on-march-24-2025\\\/\"},\"wordCount\":256,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncocyte-to-release-fourth-quarter-2024-results-on-march-24-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NjUwNyM2ODEyMTA1IzUwMDExOTgzOQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncocyte-to-release-fourth-quarter-2024-results-on-march-24-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncocyte-to-release-fourth-quarter-2024-results-on-march-24-2025\\\/\",\"name\":\"Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncocyte-to-release-fourth-quarter-2024-results-on-march-24-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncocyte-to-release-fourth-quarter-2024-results-on-march-24-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NjUwNyM2ODEyMTA1IzUwMDExOTgzOQ==\",\"datePublished\":\"2025-03-18T20:11:30+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncocyte-to-release-fourth-quarter-2024-results-on-march-24-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncocyte-to-release-fourth-quarter-2024-results-on-march-24-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncocyte-to-release-fourth-quarter-2024-results-on-march-24-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NjUwNyM2ODEyMTA1IzUwMDExOTgzOQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NjUwNyM2ODEyMTA1IzUwMDExOTgzOQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncocyte-to-release-fourth-quarter-2024-results-on-march-24-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/oncocyte-to-release-fourth-quarter-2024-results-on-march-24-2025\/","og_locale":"en_US","og_type":"article","og_title":"Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025 - Market Newsdesk","og_description":"IRVINE, Calif., March 18, 2025 (GLOBE NEWSWIRE) &#8212; Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that it will report fourth quarter 2024 financial results after the market closes on Monday, March 24, 2025. Oncocyte will host a live Zoom webinar to discuss the company&#8217;s financial results at 2:00 p.m. PT that same day. The live webinar to discuss financial results, followed by Q&amp;A, will be accessible via registration at the following link: Oncocyte Q4 2024 Earnings Webinar. An archived replay will be available after the call concludes on Oncocyte\u2019s investor relations website at https:\/\/investors.oncocyte.com. About Oncocyte Oncocyte is a leading diagnostics technology company. The company\u2019s tests are designed to help provide clarity and confidence to physicians &hellip; Continue reading \"Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/oncocyte-to-release-fourth-quarter-2024-results-on-march-24-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-18T20:11:30+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NjUwNyM2ODEyMTA1IzUwMDExOTgzOQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncocyte-to-release-fourth-quarter-2024-results-on-march-24-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncocyte-to-release-fourth-quarter-2024-results-on-march-24-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025","datePublished":"2025-03-18T20:11:30+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncocyte-to-release-fourth-quarter-2024-results-on-march-24-2025\/"},"wordCount":256,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncocyte-to-release-fourth-quarter-2024-results-on-march-24-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NjUwNyM2ODEyMTA1IzUwMDExOTgzOQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncocyte-to-release-fourth-quarter-2024-results-on-march-24-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/oncocyte-to-release-fourth-quarter-2024-results-on-march-24-2025\/","name":"Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncocyte-to-release-fourth-quarter-2024-results-on-march-24-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncocyte-to-release-fourth-quarter-2024-results-on-march-24-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NjUwNyM2ODEyMTA1IzUwMDExOTgzOQ==","datePublished":"2025-03-18T20:11:30+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncocyte-to-release-fourth-quarter-2024-results-on-march-24-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/oncocyte-to-release-fourth-quarter-2024-results-on-march-24-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncocyte-to-release-fourth-quarter-2024-results-on-march-24-2025\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NjUwNyM2ODEyMTA1IzUwMDExOTgzOQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NjUwNyM2ODEyMTA1IzUwMDExOTgzOQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncocyte-to-release-fourth-quarter-2024-results-on-march-24-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/827203","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=827203"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/827203\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=827203"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=827203"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=827203"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}